| Name | Title | Contact Details |
|---|
At Health IQ, we believe the best way to improve the health of the world is to celebrate the health conscious rather than harassing those who are not.
WELL™ Health is upending the $3.5 trillion healthcare market by helping patients and administrators break free of antiquated communication practices. This 2021 Best in KLAS for Patient Outreach software provides medical organizations with a single command center that connects the many tools they use, transforming everyday interactions between patients and the doctor`s front office.
Baystate Health is an integrated health care delivery system serving a population of nearly one million people in western Massachusetts. We are one of the largest health systems in New England with more than 12,000 employees, four hospitals, and over 80 medical practices. Baystate Medical Center has the only Level 1 Trauma Center in the region, and the only neonatal and pediatric intensive care units. University of Massachusetts Medical School-Baystate is the only regional campus of the University of Massachusetts Medical School. Baystate Medical Center has been ranked as one of the nation`s top hospitals for 2015-2016 by U.S. News & World Report and for the third time, Baystate Medical Center has been named a Magnet™ hospital for excellence in nursing services.
Iterative Health is pioneering the use of artificial intelligence-based precision medicine in gastroenterology (GI), with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD). We use advanced machine learning and computer vision to interpret endoscopic images along with other types of data, helping clinicians to better assess patients with potential GI problems. This gives practitioners enhanced capabilities in the detection, annotation, disease scoring and treatment of GI related diseases. Iterative Health is initially applying these advances towards standardizing disease severity characterization for inflammatory bowel disease. Ultimately, the company aims to establish more meaningful endpoints to serve as better predictors of both therapeutic response and disease outcomes. The company is headquartered in Cambridge, Massachusetts.
EyePoint Pharmaceuticals is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company`s pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Durasert`s proven intravitreal drug delivery platform has been safely administered to thousands of patients` eyes across four U.S. FDA-approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.